Study
Study at UCL
Being a student at UCL is about so much more than just acquiring knowledge. Studying here gives you the opportunity to realise your potential as an individual, and the skills and tools to thrive.
Research
Research at UCL
Find out more about what makes UCL research world-leading, how to access UCL expertise, and teams in the Office of the Vice-Provost (Research, Innovation and Global Engagement).
Engage
Engage with UCL
Discover the many ways you can connect with UCL, and how we work with industry, government and not-for-profit organisations to tackle tough challenges.
About
About UCL
Founded in 1826 in the heart of London, UCL is London's leading multidisciplinary university, with more than 16,000 staff and 50,000 students from 150 different countries.

Advanced Solid Tumour Trials

A list of our early phase advanced solid tumour and basket study trials which are open to recruitment at University College London Hospitals.

GO42144 A Phase I/IIa, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD7648 Monotherapy or in Combination with either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients with Advanced Malignancies
IRAS Number:	292846
Principal Investigator:	Dr. Martin Forster
Drug Class/ Treatment:	AZD7648 (KRAS G12C Inhibitor) Monotherapy and Combination with Anti-Cancer Therapies
Patient Population:	Advanced or Metastatic Solid Tumours with KRAS G12c Mutation
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

IMC-F106C-101 A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers
IRAS Number:	275567
Principal Investigator:	Dr. Heather Shaw
Drug Class/ Treatment:	IMC-F106C (Bispecific Antibody against HLA-A*02:01)
Patient Population:	HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

GARNET A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors.
IRAS Number:	219540
Principal Investigator:	Dr. Rowan Miller
Drug Class/ Treatment:	TSR-042 (Dorstarlimab) (Anti PD-L1 Monoclonal Antibody)
Patient Population:	Advanced Solid Tumours Cohort F - Patients with Recurrent or Advanced Non-endometrial and non-GI dMMR/MSI-H Solid Tumours or POLE-Mut Cancers
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

MODI-1-001 Modi-1 in Patients with Breast, Head & Neck, Ovarian or Renal Cancer: A Phase 1/2, Multicentre, Open-Label Study of Modi-1 in Patients with Breast, Head and Neck, Ovarian, or Renal Cancer
IRAS Number:	298608
Principal Investigator:	Dr. Rowan Miller
Drug Class/ Treatment:	Modi-1 - Novel Cancer Vaccine
Patient Population:	Advanced Solid Tumours: HPV-Negative Squamous Cell Carcinoma of the Head & Neck (oral cavity, oropharynx, hypopharynx, or larynx). Renal Cell Carcinoma.
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

TAK-676-1002 An Open-label, Dose Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
IRAS Number:	1006372
Principal Investigator:	Professor Martin Forster
Drug Class/ Treatment:	TAK-676 (Novel Stimulator of Interferon Genes (STING) Single Agent and in Combination with Pembrolizumab
Patient Population:	Advanced Solid Tumours: Part 2A - Squamous Cell Carcinoma of the Head & Neck (SCCHN) Part 3A - MSI-H/dMMR Colorectal Cancer
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

EP0031-101 A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of EP0031 in Patients with Advanced RET-altered Malignancies
IRAS Number:	1006061
Principal Investigator:	Professor Martin Forster
Drug Class/ Treatment:	EP0031-101 (Selective RET Inhibitor)
Patient Population:	Advanced RET-Altered Malignancies • Cohort 5 - Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) with RET • Cohort 6 - Locally Advanced or Metastatic Solid Tumours with RET-altered genes
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

Mobilize (mRNA-4359-P101) Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants with Advanced Solid Tumors
IRAS Number:	1007567
Principal Investigator:	Professor Martin Forster
Drug Class/ Treatment:	mRNA-4359-P101 (Checkpoint mRNA cancer vaccine) Combination with Checkpoint Inhibitors: · Arm 1b - Combination with Pembrolizumab
Patient Population:	Advanced Solid Tumours: Arm 1b - Melanoma and NSCLC
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

GTAEXS617-001 A Phase 1/2 open-label multicenter study to assess the safety, pharmacokinetics, and anti-tumor activity of GTAEXS617 in patients with advanced solid tumors
IRAS Number:	1006825
Principal Investigator:	Professor Martin Forster
Drug Class/ Treatment:	GTAEXS617 (Selective CDK7 Inhibitor) Dose Escalation
Patient Population:	Advanced Solid Tumours
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

SGNEGFRd2-001 A Phase 1 Study of SGN-EGFRd2 in Advanced Solid Tumors
IRAS Number:	1008649
Principal Investigator:	Professor Martin Forster
Drug Class/ Treatment:	SGN-EGFRd2 (anti-EGFR Gamma Delta T-Cell Engaging Bispecific Antibody) Dose Escalation
Patient Population:	Advanced Solid Tumours
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

DETERMINE An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers with Actionable Genomic Alterations, including Common Cancers with Rare Actionable Alterations
IRAS Number:	1004057
Principal Investigator:	Dr Martin Forster
Drug Class/ Treatment:	A - Alectinib (ALK Inhibitor) B - Atezolizumab (IgG1 Monoclonal antibody targeting PD-L1) C - Entrectinib (ROS1 & TRK Inhibitor) D - Trastuzumab (HER2 Monoclonal Antibody) + Pertuzumab (HER2 Dimerization Inhibitor) E - Vemurafenib (B-RAF enzyme Inhibitor)
Patient Population:	Adult, Paediatric and Teenage/Young Adult (TYA) Cancers with Actionable Genomic Alterations: A - Adult, Teenage/Young Adults and Paediatric patients with ALK positive cancers. B - Adult, Teenage/Young adults and Paediatric patients with cancers with high tumour mutational burden (TMB) or microsatellite instability-high (MSI-high) or proven constitutional mismatch repair deficiency (CMMRD) disposition. C - Adult, Teenage/Young Adult and Paediatric patients with C-Ros Oncogene 1 (ROS1) gene fusion positive cancers (Not NSCLC). D - Adult, Teenage/Young Adult and Paediatric patients with cancers with HER2 amplification or mutations. E - Adult patients
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

Principal Investigator(s)

Dr Martin Forster

Associate Professor, Consultant Medical Oncologist & UCL ECMC Clinical Lead

Dr. Rowan Miller

Dr Rowan Miller

Consultant Medical Oncologist

Dr Dionysis Papadatos-Pastos

Dr Dionysis Papadatos-Pastos

Consultant Medical Oncologist

Dr Michael Flynn

Consultant Medical Oncologist

Dr Sarah Benafif

Consultant Medical Oncologist

Dr Heather Shaw

Consultant Medical Oncologist

Dr Elisavet (Elsa) Papadimitraki

Consultant Medical Oncologist

Dr Rebecca Roylance

Consultant Medical Oncologist

Highlights in Medical Sciences

Millions could benefit from faster prostate cancer scan

Research

Millions could benefit from faster prostate cancer scan

Results of the PRIME trial involving UCL Medical Sciences researchers have found that a quicker, cheaper MRI scan was just as accurate at diagnosing prostate cancer as the current 30-40 minute scan.

UCL Cancer Institute awarded Athena SWAN Gold

Award

UCL Cancer Institute awarded Athena SWAN Gold

The UCL Cancer Institute has been awarded Athena SWAN Gold in recognition of its sustained commitment to advancing gender equality in higher education and research.

New Dean of Medical Sciences appointed

Announcement

New Dean of Medical Sciences appointed

Internationally recognised clinician scientist, Professor Emma Morris, will take up the role of Dean of UCL's Faculty of Medical Sciences in August 2025.